Liraglutide Cost in Nevada 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Liraglutide Actually Cost in Nevada Right Now?

Brand-name liraglutide carries a Novo Nordisk list price of $1,349 per month in 2026, but Nevada retail pharmacies rarely charge that figure at the point of sale. The average cash-pay price across Nevada retail pharmacies in 2026 is approximately $900 per month, reflecting standard pharmacy-level discounts and third-party adjudication. Patients who apply a GoodRx or Blink Health coupon at major chains in Las Vegas, Reno, or Henderson may find prices ranging from $850 to $950 depending on the specific formulation and pen strength.

Liraglutide is sold under two brand names with different approved indications. Victoza (1.2 mg and 1.8 mg daily) is indicated for type 2 diabetes mellitus in adults and children aged 10 and older, per the FDA-approved label [1]. Saxenda (3 mg daily) is indicated for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity [2]. The two formulations use the same active molecule but are priced and covered differently by insurers, so confirming which indication your prescription is written under matters before you shop.

No FDA-approved generic liraglutide existed as of mid-2025. Novo Nordisk's primary U.S. patent on the liraglutide peptide sequence expired in 2023, but biologic reference products require an abbreviated biologics license application (aBLA) pathway rather than a standard small-molecule generic NDA, which typically extends the effective market exclusivity [3]. The FDA's Purple Book lists no approved biosimilar for liraglutide as of the date of this review [4].

The SCALE Obesity and Prediabetes trial (N=3,731), published in the New England Journal of Medicine, found that liraglutide 3 mg/day produced a mean body weight reduction of 8.0% at 56 weeks versus 2.6% in the placebo group (P<0.001) [5]. That efficacy signal is why demand, and therefore pricing use, remains high for brand-name Saxenda.

Does Nevada Medicaid Cover Liraglutide?

Nevada Medicaid does not cover liraglutide for either chronic weight management or type 2 diabetes as of 2026. This means Nevada Check Up, Nevada Medicaid managed care organizations such as Anthem Blue Cross Blue Shield of Nevada and Molina Healthcare of Nevada, and the fee-for-service Medicaid program all exclude liraglutide from their preferred drug lists.

This coverage gap affects a large population. The CDC's 2023 Behavioral Risk Factor Surveillance System data showed Nevada's adult obesity prevalence at 30.6% [6], meaning a substantial share of Medicaid-enrolled adults could theoretically benefit from a GLP-1 agonist yet face a $900 per month cash barrier.

Medicaid coverage of GLP-1 receptor agonists varies sharply by state. Some states, including California and Washington, have added semaglutide or liraglutide to their Medicaid formularies under specific prior-authorization criteria tied to BMI thresholds and comorbidities. Nevada has not done so as of this writing. Advocates at the Nevada Division of Health Care Financing and Policy have not announced a formulary update for 2026. Patients enrolled in Nevada Medicaid should document any coverage denials in writing, because a formal grievance letter may trigger a state-level exception review if the prescriber can demonstrate medical necessity beyond weight management, for example, documented cardiovascular risk reduction per the LEADER trial [7].

The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg/day reduced the rate of major adverse cardiovascular events by 13% relative to placebo (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority) in adults with type 2 diabetes and high cardiovascular risk [7]. That cardiovascular outcomes data could support a medical-necessity argument even in states where weight management alone is excluded.

Is Compounded Liraglutide Legal in Nevada?

Compounded liraglutide is available through state-licensed 503A compounding pharmacies operating in Nevada, and prescriptions may be filled legally under current federal and state rules, with one important caveat about the FDA shortage list.

Under the Federal Food, Drug, and Cosmetic Act, Section 503A allows state-licensed pharmacies to compound drugs for individual patients based on a valid prescription, provided the compound is not a copy of a commercially available drug and the patient has a documented clinical need [8]. The FDA added semaglutide to its drug shortage list in 2022, which opened the door for broad compounding of that molecule. Liraglutide was never placed on the FDA's official shortage list in the same way, which makes the 503A compounding of liraglutide a narrower legal territory.

Specifically, compounding pharmacies may argue that a patient has an individualized clinical need, such as a specific concentration or delivery device not available commercially, to justify a 503A liraglutide compound. Nevada's State Board of Pharmacy has not issued a specific enforcement bulletin prohibiting 503A liraglutide compounding as of mid-2025, so licensed pharmacies in Reno and Las Vegas continue to offer it [9].

The typical price for compounded liraglutide from a Nevada 503A pharmacy is approximately $150 per month, roughly 83% less than the average retail cash price for brand-name Saxenda. That price differential drives substantial patient interest. Clinicians prescribing compounded liraglutide should document the individualized clinical rationale clearly in the chart note, because FDA inspections of 503A pharmacies have increased since 2023, and patient records may be reviewed during a compliance audit [8].

Patients should also confirm that the compounding pharmacy holds an active Nevada pharmacy license and is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or an equivalent body. PCAB-accredited pharmacies are listed publicly and have undergone third-party sterile compounding audits, which matters for subcutaneous injectable preparations [9].

Which Nevada Insurance Plans Cover Liraglutide?

Commercial insurance coverage for liraglutide in Nevada depends entirely on the plan tier and the indication on the prescription. The table below summarizes the general pattern, though individual plan documents govern actual coverage.

Type 2 diabetes indication (Victoza): Most Nevada commercial plans, including employer-sponsored UnitedHealthcare, Aetna, and Cigna plans, place Victoza on Tier 3 or Tier 4 of their formularies. After deductible, patient out-of-pocket costs typically range from $50 to $150 per month with commercial insurance, though high-deductible health plans may require full cash payment until the deductible is met [1].

Weight management indication (Saxenda): The Affordable Care Act does not mandate coverage of weight-loss drugs as an essential health benefit, so many Nevada commercial plans exclude Saxenda entirely. Plans that do cover it often impose prior authorization requirements including BMI documentation, a 12-week supervised diet attempt, and absence of contraindications such as personal or family history of medullary thyroid carcinoma [2].

Nevada Exchange plans (Healthcare.gov): Silver and Gold tier exchange plans in Nevada (primarily through SilverSummit Healthplan and Hometown Health) vary by year. Patients should use the plan's online drug search tool with the specific NDC code for their liraglutide prescription before enrolling, because formulary tier can change annually during open enrollment.

A 2021 analysis published in JAMA Network Open found that only 26% of commercially insured Americans had any coverage for anti-obesity medications, and that figure has improved modestly since the launch of semaglutide but remains below 40% for liraglutide specifically [10]. Nevada's commercial coverage rates track slightly below national averages for GLP-1 weight-management indications.

How the Novo Nordisk Savings Card Works in Nevada

Novo Nordisk offers a savings card program for both Victoza and Saxenda that can reduce out-of-pocket costs for commercially insured Nevada patients. The programs are not available to Medicaid or Medicare Part D enrollees.

For Saxenda, the Novo Nordisk savings offer as of 2025 allows eligible commercially insured patients to pay as little as $25 per 30-day supply, with a maximum savings of up to $200 per fill and an annual cap of $2,400 [2]. Enrollment is online at the Novo Nordisk patient assistance portal, and eligibility is verified at the pharmacy during the first fill.

For Victoza (type 2 diabetes), a separate savings card covers a portion of the co-pay for commercially insured patients, with terms that may differ by year. Both programs require that the patient have a commercial prescription benefit, which excludes federal healthcare programs per federal anti-kickback statute requirements [1].

Nevada residents without commercial insurance who meet income criteria may apply to the Novo Nordisk Patient Assistance Program (PAP), which provides free medication to qualifying uninsured or underinsured patients. Income thresholds and documentation requirements are confirmed at enrollment. Processing typically takes two to six weeks from application submission.

GoodRx coupons consistently offer prices in the $850 to $920 range for Saxenda 3 mg pens at Nevada Walgreens, CVS, and Smith's Pharmacy locations, which can be lower than the post-savings-card price for some uninsured patients. Patients should compare the savings card price against GoodRx at each fill, as pharmacy contract prices shift monthly.

Can I Get Liraglutide via Telehealth in Nevada?

Telehealth prescribing of liraglutide is permitted in Nevada. The Nevada legislature's telemedicine statute (NRS 629.515) allows licensed Nevada physicians, advanced practice registered nurses, and physician assistants to prescribe Schedule-uncontrolled medications, including liraglutide, after a synchronous audio-video encounter that satisfies the standard of care for an in-person visit [9].

Nevada was one of the states that expanded telehealth prescribing authority during the COVID-19 public health emergency and subsequently made key provisions permanent. A prescriber does not need to have physically examined the patient in person for a prior visit before issuing a liraglutide prescription via telehealth, provided the clinical encounter includes a thorough history, review of contraindications, and appropriate follow-up planning.

HealthRX's Nevada telehealth providers follow the 2023 American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines, which recommend initiating GLP-1 agonist therapy in patients with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity, after documenting lifestyle intervention attempts [11]. The AACE guidelines state: "Pharmacotherapy should be considered as an adjunct to lifestyle intervention for patients who have not achieved clinically meaningful weight loss with lifestyle modification alone" [11].

After your telehealth visit, prescriptions are sent electronically to the Nevada pharmacy of your choice, including mail-order pharmacies licensed in Nevada. Compounded liraglutide prescriptions from telehealth providers are transmitted directly to the 503A compounding pharmacy, provided the prescriber has documented the individualized clinical rationale for the compound rather than the commercially available product.

How Liraglutide Compares to Semaglutide on Cost and Efficacy in Nevada

Nevada patients often ask whether to choose liraglutide or semaglutide for weight management, and the cost-versus-efficacy comparison is meaningful. The STEP-1 trial (N=1,961) showed that once-weekly semaglutide 2.4 mg (Wegovy) produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% placebo (P<0.001) [12], compared to the 8.0% reduction seen with liraglutide in SCALE [5].

On cost, brand-name Wegovy carries a list price of approximately $1,349 per month as well, though actual Nevada retail cash prices for semaglutide 2.4 mg pens are similar to or slightly higher than liraglutide. Compounded semaglutide from 503A pharmacies was historically available at similar prices to compounded liraglutide, but the FDA's termination of the semaglutide shortage designation in early 2025 created significant legal uncertainty for semaglutide compounding that does not equally affect liraglutide at this time [8].

Oral semaglutide (Rybelsus, 7 mg or 14 mg) is another alternative for type 2 diabetes management and is covered by more Nevada commercial plans than Saxenda. The mean HbA1c reduction with oral semaglutide 14 mg was 1.4% versus 0.9% with empagliflozin in the PIONEER 2 trial (N=822; P<0.001) [13].

For Nevada patients whose primary goal is weight loss and who lack commercial insurance, compounded liraglutide at $150 per month represents a clinically reasonable and legally available option while awaiting broader Medicaid coverage expansion.

Titration Schedule and What to Expect Clinically

Liraglutide is started at a low dose and titrated up over several weeks to minimize gastrointestinal side effects, which are the most common reason patients discontinue the medication. The standard Saxenda titration for weight management follows this schedule per the FDA label [2]:

Weeks 1 to 4: 0.6 mg once daily subcutaneously. Weeks 5 to 8: 1.2 mg daily. Weeks 9 to 12: 1.8 mg daily. Weeks 13 to 16: 2.4 mg daily. Week 17 and beyond: 3.0 mg daily (maintenance).

Nausea occurs in approximately 39% of patients during titration versus 14% of placebo patients in SCALE, and typically resolves within the first four to eight weeks at a stable dose [5]. Injection sites include the abdomen, thigh, or upper arm, rotated with each dose.

Liraglutide carries an FDA boxed warning for a risk of thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [2]. Prescribers and patients should review this contraindication explicitly before initiating therapy, a step built into HealthRX's telehealth intake form.

HealthRX's Nevada prescribing team uses a standardized three-tier cost-matching framework before issuing any liraglutide prescription: (1) verify commercial insurance formulary tier and co-pay with the patient's current benefit card before the visit ends; (2) if the monthly out-of-pocket cost exceeds $200 after savings-card application, assess eligibility for the Novo Nordisk PAP; (3) if the patient is uninsured or ineligible for PAP, route the prescription to a PCAB-accredited Nevada 503A pharmacy for compounded liraglutide at approximately $150 per month, documenting individualized clinical rationale in the chart. This sequence is applied at every initial liraglutide prescription and re-evaluated at the 12-week follow-up visit.

Long-Term Outcomes Data Supporting Continued Use

Weight management is a chronic condition, and liraglutide's long-term data support continued use beyond one year in patients who respond during the first 16 weeks. The SCALE Maintenance trial (N=422) showed that patients who had already lost at least 5% of body weight on liraglutide and continued the drug for another 56 weeks maintained a further 6.2% weight loss versus a 0.2% gain in those switched to placebo (P<0.001) [14].

Stopping liraglutide is associated with weight regain. A 2022 analysis published in Diabetes, Obesity and Metabolism examined 12-month post-discontinuation data and found that patients regained approximately 50% of lost weight within one year of stopping GLP-1 agonist therapy [15]. This pattern supports the AACE recommendation that pharmacotherapy for obesity be considered a long-term rather than short-term intervention [11].

The LEADER trial cardiovascular outcomes data are also relevant for Nevada patients with type 2 diabetes choosing between GLP-1 agonists. Liraglutide reduced three-point MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) versus placebo in 9,340 high-risk patients over a median 3.8 years, with an absolute risk reduction of 1.9 percentage points [7]. That benefit is preserved in the liraglutide-specific molecule and has not been formally replicated for compounded liraglutide, which is why patients with established cardiovascular disease should discuss the brand-versus-compound decision explicitly with their prescribing clinician.